Do analysts prefer TCRX or CDIO?

TScan Therapeutics presently has a consensus price target of $2.67, suggesting a potential upside of 863.04%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to TCRX or CDIO?

In the previous week, TScan Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Cardio Diagnostics. TScan Therapeutics' average media sentiment score of 0.00 beat Cardio Diagnostics' score of -0.71 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer CDIO or ESLA?

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,804.76%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CDIO or ESLA?

In the previous week, Estrella Immunopharma had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Cardio Diagnostics. Estrella Immunopharma's average media sentiment score of 0.79 beat Cardio Diagnostics' score of -0.71 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Estrella Immunopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ATOS or CDIO?

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 726.56%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ATOS or CDIO?

In the previous week, Atossa Genetics had 9 more articles in the media than Cardio Diagnostics. MarketBeat recorded 10 mentions for Atossa Genetics and 1 mentions for Cardio Diagnostics. Atossa Genetics' average media sentiment score of 0.73 beat Cardio Diagnostics' score of -0.71 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer CDIO or JSPR?

Jasper Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,187.23%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Does the media refer more to CDIO or JSPR?

In the previous week, Jasper Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Cardio Diagnostics. Jasper Therapeutics' average media sentiment score of 0.29 beat Cardio Diagnostics' score of -0.71 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Jasper Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardio Diagnostics (CDIO) Competitors

$1.96 -0.04 (-2.00%)

Closing price 10/7/2026 03:59 PM Eastern

Extended Trading

$2.00 +0.04 (+2.24%)

As of 10/7/2026 07:59 PM Eastern

Compare

CDIO vs. TCRX, ESLA, ATOS, JSPR, and NEUP

Should you buy Cardio Diagnostics stock or one of its competitors? Cardio Diagnostics's main competitors and comparable companies include TScan Therapeutics (TCRX), Estrella Immunopharma (ESLA), Atossa Genetics (ATOS), Jasper Therapeutics (JSPR), and Neuphoria Therapeutics (NEUP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardio Diagnostics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

TScan Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

Cardio Diagnostics has lower revenue, but higher earnings than TScan Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.82	-$129.77M	-$0.91	N/A
Cardio Diagnostics	$10K	580.16	-$6.50M	-$2.92	N/A

TScan Therapeutics presently has a consensus price target of $2.67, suggesting a potential upside of 863.04%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TScan Therapeutics has a net margin of -1,655.35% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

In the previous week, TScan Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Cardio Diagnostics. TScan Therapeutics' average media sentiment score of 0.00 beat Cardio Diagnostics' score of -0.71 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

TScan Therapeutics beats Cardio Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Estrella Immunopharma?

Cardio Diagnostics (NASDAQ:CDIO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Estrella Immunopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Estrella Immunopharma's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Estrella Immunopharma	N/A	N/A	-328.72%

Cardio Diagnostics has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	580.16	-$6.50M	-$2.92	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Cardio Diagnostics. Estrella Immunopharma's average media sentiment score of 0.79 beat Cardio Diagnostics' score of -0.71 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Estrella Immunopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,804.76%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cardio Diagnostics has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Summary

Estrella Immunopharma beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Atossa Genetics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 726.56%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardio Diagnostics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Cardio Diagnostics	$10K	580.16	-$6.50M	-$2.92	N/A

In the previous week, Atossa Genetics had 9 more articles in the media than Cardio Diagnostics. MarketBeat recorded 10 mentions for Atossa Genetics and 1 mentions for Cardio Diagnostics. Atossa Genetics' average media sentiment score of 0.73 beat Cardio Diagnostics' score of -0.71 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Summary

Atossa Genetics beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Jasper Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Jasper Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,187.23%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Jasper Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Cardio Diagnostics. Jasper Therapeutics' average media sentiment score of 0.29 beat Cardio Diagnostics' score of -0.71 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Jasper Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardio Diagnostics has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market.

Jasper Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Cardio Diagnostics has higher revenue and earnings than Jasper Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	580.16	-$6.50M	-$2.92	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Summary

Jasper Therapeutics beats Cardio Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Neuphoria Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 104.68%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Neuphoria Therapeutics' return on equity of -38.31% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

In the previous week, Cardio Diagnostics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 beat Cardio Diagnostics' score of -0.71 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Cardio Diagnostics	Negative

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.6% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cardio Diagnostics has lower revenue, but higher earnings than Neuphoria Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	15.81	-$13.45M	-$6.22	N/A
Cardio Diagnostics	$10K	580.16	-$6.50M	-$2.92	N/A

Summary

Neuphoria Therapeutics beats Cardio Diagnostics on 9 of the 15 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.92M	$3.84B	$7.16B	$13.44B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.67	13.73	274.56	26.10
Price / Sales	580.16	1,207.54	581.05	87.31
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.51	15.97	10.73	6.27
Net Income	-$6.50M	-$22.65M	$3.50B	$382.03M
7 Day Performance	2.08%	-2.60%	-0.39%	-0.52%
1 Month Performance	N/A	-11.94%	-6.12%	-4.80%
1 Year Performance	-56.83%	10.58%	4.14%	-0.71%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.7066 of 5 stars	$1.96 -2.0%	N/A	-55.1%	$5.92M	$10K	N/A	1
TCRX TScan Therapeutics	2.7281 of 5 stars	$0.32 +0.8%	$2.67 +733.3%	-85.9%	$21.69M	$7.11M	N/A	142
ESLA Estrella Immunopharma	1.6909 of 5 stars	$0.48 +3.5%	$8.00 +1,580.7%	-66.7%	$20.71M	N/A	N/A	N/A	News Coverage Gap Down
ATOS Atossa Genetics	2.2751 of 5 stars	$2.08 +4.3%	$20.33 +879.9%	-83.8%	$20.70M	N/A	N/A	14	News Coverage Analyst Revision
JSPR Jasper Therapeutics	1.6768 of 5 stars	$0.62 -1.5%	$7.33 +1,090.5%	-76.6%	$20.60M	N/A	N/A	22	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. TCRX, ESLA, ATOS, JSPR, and NEUP

How does Cardio Diagnostics compare to TScan Therapeutics?

Summary

How does Cardio Diagnostics compare to Estrella Immunopharma?

Summary

How does Cardio Diagnostics compare to Atossa Genetics?

Summary

How does Cardio Diagnostics compare to Jasper Therapeutics?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. TCRX, ESLA, ATOS, JSPR, and NEUP

How does Cardio Diagnostics compare to TScan Therapeutics?

Which has more volatility and risk, TCRX or CDIO?

Which has better valuation & earnings, TCRX or CDIO?

Do analysts prefer TCRX or CDIO?

Do institutionals and insiders hold more shares of TCRX or CDIO?

Is TCRX or CDIO more profitable?

Does the media refer more to TCRX or CDIO?

Summary

How does Cardio Diagnostics compare to Estrella Immunopharma?

Is CDIO or ESLA more profitable?

Which has stronger earnings and valuation, CDIO or ESLA?

Does the media favor CDIO or ESLA?

Do analysts prefer CDIO or ESLA?

Do institutionals & insiders have more ownership in CDIO or ESLA?

Which has more risk & volatility, CDIO or ESLA?

Summary

How does Cardio Diagnostics compare to Atossa Genetics?

Is ATOS or CDIO more profitable?

Do analysts recommend ATOS or CDIO?

Which has preferable earnings & valuation, ATOS or CDIO?

Does the media refer more to ATOS or CDIO?

Do institutionals and insiders believe in ATOS or CDIO?

Which has more risk & volatility, ATOS or CDIO?

Summary

How does Cardio Diagnostics compare to Jasper Therapeutics?

Do analysts prefer CDIO or JSPR?

Does the media refer more to CDIO or JSPR?

Do institutionals & insiders believe in CDIO or JSPR?

Which has more risk & volatility, CDIO or JSPR?

Is CDIO or JSPR more profitable?

Which has preferable earnings and valuation, CDIO or JSPR?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Do analysts rate NEUP or CDIO?

Is NEUP or CDIO more profitable?

Which has more risk and volatility, NEUP or CDIO?

Does the media refer more to NEUP or CDIO?

Do insiders and institutionals believe in NEUP or CDIO?

Which has better valuation & earnings, NEUP or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools